Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

July 2, 2020

Altered Structural Brain Networks Related to Adrenergic/Muscarinic Receptor Autoantibodies in Chronic Fatigue Syndrome

Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging
Hiroyuki FujiiNoriko Sato
June 4, 2020

Preliminary ICF core set for patients with myalgic encephalomyelitis/chronic fatigue syndrome in rehabilitation medicine

Journal of Rehabilitation Medicine
Indre Bileviciute-LjungarJan Ekholm
June 23, 2020

Impact of myalgic encephalomyelitis on treatment of comorbidities: A lived experience

Work : a Journal of Prevention, Assessment, and Rehabilitation
Denise Lopez-Majano
May 15, 2020
Review
Open Access

A systematic review of metabolomic dysregulation in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis/Systemic Exertion Intolerance Disease (CFS/ME/SEID)

Journal of Translational Medicine
Teilah Kathryn HuthSonya Marshall-Gradisnik
June 30, 2020
Preprint
Open Access

FUNGAL DYSBIOSIS CORRELATES WITH THE DEVELOPMENT OF TUMOUR-INDUCED CACHEXIA IN MICE

BioRxiv : the Preprint Server for Biology
Daniela Leite JabesL. R. Nunes
May 16, 2020
Open Access

Fallout from the Covid-19 pandemic - should we prepare for a tsunami of post viral depression?

Irish Journal of Psychological Medicine
Declan LyonsKevin Glynn
June 23, 2020

Post-exertional symptoms distinguish myalgic encephalomyelitis/chronic fatigue syndrome subjects from healthy controls

Work : a Journal of Prevention, Assessment, and Rehabilitation
Lariel J MateoJ Mark VanNess
June 23, 2020
Comment / Editorial
Open Access

Research, recommendations and lived/personal experience with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

Work : a Journal of Prevention, Assessment, and Rehabilitation
Amy Mooney
May 16, 2020
Open Access

Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study

Frontiers in Medicine
Ingrid G RekelandØystein Fluge
June 23, 2020

Clinically accessible tools for documenting the impact of orthostatic intolerance on symptoms and function in ME/CFS

Work : a Journal of Prevention, Assessment, and Rehabilitation
Jihyun LeeSuzanne D Vernon
June 6, 2020
Open Access

Paediatric chronic fatigue syndrome patients' and parents' perceptions of recovery

BMJ Paediatrics Open
Matthew Robert HarlandEsther Crawley
April 17, 2020
Open Access

Metabolic Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Not Due to Anti-mitochondrial Antibodies

Frontiers in Medicine
Isabell NilssonAnders Rosén

Sign up to follow this feed and discover related papers.

Related Feeds

ALS

Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

ALS & FTD: TDP-43

ALS shares with a considerable proportion of FTD cases the same neuropathological substrate, namely, inclusions of abnormally phosphorylated protein tdp-43 (ptdp-43). Here are the latest discoveries pertaining to ptdp-43 and these diseases.

ALS - Pathogenic Mechanisms

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

ALS - Phenotypes

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating phenotypes associated with this genetically heterogeneous disorder.

ALS: Genetics

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here are the latest discoveries pertaining to this disease.

ALS: Stress Granules

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by cytoplasmic protein aggregates within motor neurons. TDP-43 is an ALS-linked protein that is known to regulate splicing and storage of specific mRNAs into stress granules, which have been implicated in formation of ALS protein aggregates. Here is the latest research.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS therapies here.

ALS: Transposon de-silencing

Transposon silencing is a form of transcriptional gene silencing. These gene silencing mechanisms are impaired in Amyotrophic lateral sclerosis (ALS). Here are the latest discoveries pertaining to transposon silencing and this disease.

Antisense Oligonucleotide - Therapies For ALS

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

© 2020 Meta ULC. All rights reserved
/feed-previews/chronic-fatigue-syndrome/68dbfb0f-e560-4919-bf8f-e99721cadd22